Drug Profile


Alternative Names: Actilyse; Activacin; Activase; Cathflo; G-11021; G-11035; G-11044; GMK-527; GRTPA; IV rt-PA; Recombinant tissue plasminogen activator - Boehringer; RG-3626; rt-PA - Boehringer; rTPA - Boehringer; t-PA - Boehringer; Tissue plasminogen activator - Boehringer; Tissue type plasminogen activator - Boehringer

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim
  • Developer Boehringer Ingelheim; Genentech; Washington University School of Medicine
  • Class Plasminogen activator enzymes; Recombinant proteins; Thrombolytics
  • Mechanism of Action Plasminogen activators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Catheter thrombosis; Myocardial infarction; Pulmonary embolism; Stroke
  • Phase III Deep vein thrombosis

Most Recent Events

  • 09 May 2017 Genentech terminates the phase IIIb PRISMS trial for Stroke in USA (NCT02072226)
  • 01 Jan 2017 Genentech completes the phase III ATTRACT trial in Deep vein thrombosis (In adolescents, In adults, In the elderly) in USA (IV) (NCT00790335)
  • 01 Nov 2016 Boehringer Ingelheim initiates enrolment in a phase III trial for Stroke in China (NCT02930837)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top